{"id":"donor-lymphocyte-infusion","safety":{"commonSideEffects":["Graft-versus-host disease","Cytopenia","Infections"],"contraindications":["Active severe graft-versus-host disease"]},"_chembl":null,"modality":"Biologic","_dailymed":null,"mechanism":{"explanation":"DLI works by transferring functional immune cells from the original stem cell donor to the transplant recipient. These donor lymphocytes recognize and attack residual cancer cells through immune recognition mechanisms, particularly the graft-versus-leukemia effect, while also carrying risk of graft-versus-host disease.","oneSentence":"Infuses donor T-cells and other lymphocytes to enhance immune-mediated graft-versus-tumor effects against residual malignant cells."},"_scrapedAt":"2026-03-28T02:34:21.875Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_claudeStub":{"ts":1779123831,"model":"claude-sonnet-4-5-20250929"},"competitors":[{"name":"Azacitidine","brand":"Vidaza","company":"Celgene","rationale":"Used for relapsed AML post-transplant maintenance"},{"name":"Imatinib","brand":"Gleevec","company":"Novartis","rationale":"Treatment for relapsed CML post-transplant"}],"description":"Donor Lymphocyte Infusion (DLI) is a cellular immunotherapy that involves transfusing immune cells from a stem cell donor to a transplant recipient. It is used to treat relapsed hematologic malignancies after allogeneic stem cell transplantation by enhancing the graft-versus-tumor effect.","indications":{"approved":[{"status":"investigational","condition":"Relapsed chronic myeloid leukemia post-transplant","patientPopulation":"Adult, post-allogeneic stem cell transplant"},{"status":"investigational","condition":"Relapsed acute myeloid leukemia post-transplant","patientPopulation":"Adult, post-allogeneic stem cell transplant"},{"status":"investigational","condition":"Mixed chimerism post-transplant","patientPopulation":"Adult, post-allogeneic stem cell transplant"}]},"trialDetails":[{"nctId":"NCT03173937","phase":"PHASE1, PHASE2","title":"Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome","status":"RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2017-06-13","conditions":"Severe Aplastic Anemia, Hypo-Plastic MDS, Myelodysplastic Syndrome (MDS)","enrollment":37},{"nctId":"NCT03910452","phase":"EARLY_PHASE1","title":"Haploidentical Transplant for People With Chronic Granulomatous Disease (CGD) Using Alemtuzumab, Busulfan and TBI With Post-Transplant Cyclophosphamide","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-10-28","conditions":"Chronic Granulomatous Disease","enrollment":4},{"nctId":"NCT03180216","phase":"PHASE1","title":"T-Lymphocytes for Prevention or Treatment of Viral Infections Following Hematopoietic Stem Cell Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's National Research Institute","startDate":"2017-02-15","conditions":"Viral Infections, Bone Marrow Transplant Infection","enrollment":32},{"nctId":"NCT06872333","phase":"PHASE2","title":"Allo HSCT for High Risk Hemoglobinopathies","status":"RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2024-11-19","conditions":"Graft Failure, Sickle Cell Disease, Hemoglobinopathies","enrollment":62},{"nctId":"NCT05226455","phase":"PHASE1, PHASE2","title":"Venetoclax in Patients With MDS or AML in Relapse After AHSCT","status":"ACTIVE_NOT_RECRUITING","sponsor":"Groupe Francophone des Myelodysplasies","startDate":"2022-11-23","conditions":"MDS, AML","enrollment":55},{"nctId":"NCT06508138","phase":"PHASE1","title":"Clinical Trial Assessing the Safety and Immunologic Correlates of Heterologous Prime-Boost With pNGVL4a-Sig/E7(Detox)/HSP70 and TA-HPV in Healthy Donors Followed by Peripheral Blood Collection","status":"ENROLLING_BY_INVITATION","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2023-10-18","conditions":"HPV 16 Infection, HPV-Related Carcinoma, Recurrence","enrollment":24},{"nctId":"NCT04713046","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of Allogeneic HPV-specific T Cells in Adults With Recurrent or Metastatic HPV16+ Cancers","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2023-10-18","conditions":"HPV 16+ Recurrent or Metastatic Cancer","enrollment":24},{"nctId":"NCT07285668","phase":"NA","title":"Prophylactic TCRaB+ and CD19+ Depleted Donor Lymphocyte Infusion After Allogeneic Stem Cell Transplant in High-Risk Patients With Hematologic Malignancies","status":"RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2026-02-26","conditions":"Hematologic Malignancies","enrollment":38},{"nctId":"NCT07441291","phase":"PHASE3","title":"CD19 CAR-T vs DLI for Post-HSCT MRD in Ph- ALL: A RCT","status":"RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2025-11-30","conditions":"B ALL, Allogenetic Hematopoietic Stem Cell Transplantation, MRD-positive","enrollment":70},{"nctId":"NCT06297629","phase":"PHASE2","title":"A Phase I/II Trial to Assess the Efficacy and Toxicity of ASTX727 (Oral Decitabine/Cedazuridine) for the Treatment of Hematological Neoplasms After Allogeneic Stem Cell Transplantation","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-07-01","conditions":"Allogeneic Stem Cell Transplantation","enrollment":""},{"nctId":"NCT04620681","phase":"PHASE1, PHASE2","title":"CD8 Depleted, Non-engrafting, HLA Mismatched Unrelated Infusion With MDS and Secondary AML","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2021-01-14","conditions":"Myelodysplastic Syndromes, Secondary Acute Myeloid Leukemia","enrollment":19},{"nctId":"NCT03425526","phase":"PHASE1","title":"Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-03-15","conditions":"Hematopoietic and Lymphoid Cell Neoplasm, Immunocompromised","enrollment":16},{"nctId":"NCT02210078","phase":"PHASE2","title":"Donor Cytomegalovirus-Specific Cytotoxic T-Lymphocytes in Treating Patients With a Persistent Cytomegalovirus Infection","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-02-19","conditions":"Cytomegaloviral Infection, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm","enrollment":49},{"nctId":"NCT06158828","phase":"PHASE1, PHASE2","title":"Pilot Study of Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical Transplant in AML","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2024-05-15","conditions":"AML, Childhood, Aml, Acute Myeloid Leukemia, Pediatric","enrollment":68},{"nctId":"NCT03032783","phase":"PHASE2","title":"A Two Step Approach to Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematologic Malignancies-Increasing GVT Effects Without Increasing Toxicity","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2017-01-31","conditions":"Hematopoietic and Lymphoid Cell Neoplasm","enrollment":51},{"nctId":"NCT05327023","phase":"PHASE1, PHASE2","title":"Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-05-23","conditions":"Hematologic Neoplasms","enrollment":430},{"nctId":"NCT04180059","phase":"PHASE1","title":"Phase I Study of CTL Anti-DP Infusion Post-hematopoietic Stem Cell Transplantation","status":"RECRUITING","sponsor":"Nantes University Hospital","startDate":"2020-02-09","conditions":"Haematologic Disease","enrollment":6},{"nctId":"NCT07366801","phase":"PHASE2, PHASE3","title":"Co-infusion of Treg-enriched Donor Lymphocytes With CD3-depleted Hematopoietic Stem Cell Graft to Prevent Graft-versus Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation Among Children With Hematologic Malignancies","status":"RECRUITING","sponsor":"Federal Research Institute of Pediatric Hematology, Oncology and Immunology","startDate":"2025-09-03","conditions":"Acute Myeloid Leukemia, Relapsed, Acute Lymphoblastic Leukemia, High Risk, Acute Myeloid Leukemia, High Risk","enrollment":64},{"nctId":"NCT04691622","phase":"PHASE1","title":"Adoptive T Lymphocyte Administration for Chronic Norovirus Treatment in Immunocompromised Hosts","status":"RECRUITING","sponsor":"Children's National Research Institute","startDate":"2022-03-17","conditions":"Viral Infection, Hematopoietic Stem Cell Transplantation (HSCT), Primary Immunodeficiency Disorders (PID)","enrollment":48},{"nctId":"NCT07162038","phase":"PHASE1","title":"Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA-Haploidentical Hematopoietic Cell Transplantation","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-11-14","conditions":"Hematologic Malignancies, Hematologic Neoplasms","enrollment":155},{"nctId":"NCT07319793","phase":"NA","title":"Pre-DLI or Pro-DLI in Relapsed/Refractory Myeloid Neoplasms After HSCT","status":"NOT_YET_RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2026-01-01","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndromes (MDS)","enrollment":200},{"nctId":"NCT07052370","phase":"PHASE1","title":"TCRαβ-depleted Progenitor Cell Graft With Early Memory T-cell DLI, Plus Selected Use of Blinatumomab, in naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2025-09-25","conditions":"Hematologic Malignancy","enrollment":30},{"nctId":"NCT07307053","phase":"PHASE1, PHASE2","title":"Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2)","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2026-01-01","conditions":"Rare Malignant Neoplasm, Advanced Solid Tumors, Metastatic Solid Tumors","enrollment":600},{"nctId":"NCT05991973","phase":"PHASE2","title":"Low-dose Chidamide Maintenance Therapy After Allo-HSCT for T-cell Acute Lymphoblastic Leukemia or T-cell Lymphomas","status":"COMPLETED","sponsor":"Zhejiang University","startDate":"2023-07-15","conditions":"T Lymphoblastic Leukemia/Lymphoma","enrollment":44},{"nctId":"NCT07254793","phase":"PHASE1","title":"Prophylactic and Therapeutic DLI-X for Leukemia Relapse After HCT","status":"NOT_YET_RECRUITING","sponsor":"University of Arizona","startDate":"2026-02-28","conditions":"Acute Lymphoid Leukemia, Acute Myeloid Leukemia, Acute Undifferentiated Leukemia (AUL)","enrollment":94},{"nctId":"NCT05806749","phase":"PHASE1","title":"Immunological Tolerance in Patients With Mismatched Kidney Transplants","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of California, Los Angeles","startDate":"2023-07-07","conditions":"End Stage Kidney Disease, Immunological Tolerance, Kidney Transplant Failure and Rejection","enrollment":16},{"nctId":"NCT07070323","phase":"PHASE1, PHASE2","title":"A Multicenter, Open-Label, Non-Randomized, Single-Arm Clinical Study of Nanobody CD5-CAR T Cell Therapy for Refractory/Relapsed T Lymphocyte Malignancies","status":"RECRUITING","sponsor":"Beijing GoBroad Hospital","startDate":"2025-07-09","conditions":"T-Cell Acute Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, in Relapse, Refractory Acute Lymphoblastic Leukemia","enrollment":54},{"nctId":"NCT05772273","phase":"NA","title":"PD-1 Inhibitor, Azacitidine and Low-dose DLI in AML Relapse After Allo-HSCT","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2023-03-15","conditions":"Acute Myeloid Leukemia","enrollment":43},{"nctId":"NCT03665675","phase":"EARLY_PHASE1","title":"Donor Virus-Specific CMV or AdV CTL to Treat CMV or AdV Reactivation or Disease After Solid Organ or HCT","status":"RECRUITING","sponsor":"Sumithira Vasu","startDate":"2020-11-07","conditions":"Allogeneic Hematopoietic Stem Cell Transplantation Recipient, Cytomegalovirus, Donor","enrollment":20},{"nctId":"NCT02050347","phase":"PHASE1","title":"Activated T Lymphocytes Expressing CARs, Relapsed CD19+ Malignancies Post-Allo HSCT(CARPASCIO)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Baylor College of Medicine","startDate":"2014-04","conditions":"Non-Hodgkin's Lymphoma, B-Cell ALL, B-Cell CLL","enrollment":7},{"nctId":"NCT05400122","phase":"PHASE1","title":"Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer","status":"SUSPENDED","sponsor":"David Wald","startDate":"2022-09-09","conditions":"Colorectal Cancer, Hematologic Malignancy, Rectum Cancer","enrollment":12},{"nctId":"NCT07225972","phase":"PHASE3","title":"Phase 3 Randomized Trial for Refractory ADV or CMV Infection With Family Matched CTLs and Standard of Care (SOC) vs SOC Alone","status":"NOT_YET_RECRUITING","sponsor":"New York Medical College","startDate":"2026-12-01","conditions":"CMV, AdV Infection, AdV Reactivation","enrollment":69},{"nctId":"NCT02684162","phase":"PHASE2","title":"Guadecitabine and Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapsing After Allogeneic Stem Cell Transplant","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2016-06-22","conditions":"Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome","enrollment":55},{"nctId":"NCT05031897","phase":"PHASE2","title":"Two Step Haplo With Radiation Conditioning","status":"RECRUITING","sponsor":"Thomas Jefferson University","startDate":"2021-10-25","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Adult T-Cell Leukemia/Lymphoma","enrollment":63},{"nctId":"NCT04318678","phase":"PHASE1","title":"CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2020-07-29","conditions":"AML/MDS, B-ALL, T-ALL","enrollment":108},{"nctId":"NCT06529731","phase":"PHASE2","title":"Interferon-γ (IFN-γ) With Donor Leukocyte Infusion to Treat Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes Post Allogeneic Hematopoietic Stem Cell Transplantation","status":"RECRUITING","sponsor":"Sawa Ito, MD","startDate":"2024-09-23","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndromes","enrollment":45},{"nctId":"NCT05358808","phase":"PHASE2","title":"ACHIEVE - Efficacy and Effectiveness of Adoptive Cellular tHerapy wIth Ex-Vivo Expanded Allogeneic γδ T-lymphocytes (TCB008) for Patients With Refractory or Relapsed Acute Myeloid Leukaemia (AML)","status":"TERMINATED","sponsor":"TC Biopharm","startDate":"2022-08-15","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndromes","enrollment":16},{"nctId":"NCT06307054","phase":"PHASE1","title":"CLL-1 CAR-NK Cells for Relapsed/Refractory AML","status":"RECRUITING","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2024-04-01","conditions":"Relapsed Adult AML, Refractory AML","enrollment":24},{"nctId":"NCT06358638","phase":"PHASE2","title":"Sickle Cell Disease Transplant Using a Nonmyeloablative Approach for Patients With Anti-donor Red Cell Antibody","status":"RECRUITING","sponsor":"Children's National Research Institute","startDate":"2024-04-03","conditions":"Sickle Cell Disease","enrollment":12},{"nctId":"NCT05385705","phase":"PHASE1","title":"A Study of Allogenic Natural Killer Cells in Combination With Trastuzumab and Pertuzumab in Adult Patients With Refractory Metastatic Her2 Positive Breast Cancer. NK-ACT-BC_2020","status":"TERMINATED","sponsor":"Vall d'Hebron Institute of Oncology","startDate":"2022-05-11","conditions":"Breast Neoplasms","enrollment":2},{"nctId":"NCT06034535","phase":"PHASE2","title":"CD62L Depleted Donor Lymphocyte Infusion With T Cell Depleted Haploidentical Hematopoietic Stem Cell Transplantation","status":"RECRUITING","sponsor":"Hong Kong Children's Hospital","startDate":"2023-09-01","conditions":"Hematopoietic Organs; Disorder","enrollment":23},{"nctId":"NCT03712878","phase":"PHASE2","title":"2-Step Approach to Stem Cell Transplant in Treating Participants With Hematological Malignancies","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2018-09-19","conditions":"Hematopoietic and Lymphoid Cell Neoplasm","enrollment":10},{"nctId":"NCT03531736","phase":"PHASE1","title":"T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Conditioned With a Reduced Intensity Regimen in Patients With Hematologic Malignancies and Aplastic Anemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2018-05-09","conditions":"Myeloid Diseases","enrollment":17},{"nctId":"NCT01889381","phase":"PHASE2","title":"Human Craniomaxillofacial Allotransplantation","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2012-08","conditions":"Facial Injuries, Traumatic Wounds and Injuries, Craniofacial Injuries","enrollment":15},{"nctId":"NCT04362293","phase":"PHASE2","title":"Reduced Intensity Transplantation for Severe Sickle Cell Disease","status":"SUSPENDED","sponsor":"St. Jude Children's Research Hospital","startDate":"2020-04-30","conditions":"Sickle Cell Disease","enrollment":40},{"nctId":"NCT06909110","phase":"PHASE1, PHASE2","title":"Viral Specific T-Lymphocytes to Treat Infection With Adenovirus, Cytomegalovirus or Epstein-Barr Virus in Patients With Compromised Immunity","status":"RECRUITING","sponsor":"Jessie L. Alexander","startDate":"2025-04-30","conditions":"Adenovirus, Cytomegalovirus Infections, Epstein-Barr Virus Infections","enrollment":25},{"nctId":"NCT03266627","phase":"PHASE2","title":"Adenovirus-specific Cytotoxic T-lymphocytes for Refractory Adenovirus Infection","status":"RECRUITING","sponsor":"New York Medical College","startDate":"2018-11-01","conditions":"Adenovirus, Primary Immune Deficiency Disorder","enrollment":20},{"nctId":"NCT04013802","phase":"PHASE1","title":"TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT.","status":"RECRUITING","sponsor":"Baylor College of Medicine","startDate":"2021-03-08","conditions":"Viral Infection","enrollment":47},{"nctId":"NCT07105579","phase":"PHASE2","title":"Effectiveness and Safety of Blinatumomab and Donor Lymphocyte Infusion in Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation for High-risk Ph Negative B Cell Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2025-08","conditions":"Leukemia, Relapse","enrollment":31},{"nctId":"NCT06158100","phase":"PHASE1","title":"Venetoclax in Combination With Azacitidine (VEN/AZA) Followed by Donor Lymphocyte Infusion (DLI) for Patients With Very High-Risk Acute Myeloid Leukemia (AML) Undergoing Allogeneic Hematopoietic Cell Transplant (HCT)","status":"SUSPENDED","sponsor":"Antonio M Jimenez Jimenez","startDate":"2024-12-04","conditions":"Acute Myeloid Leukemia","enrollment":25},{"nctId":"NCT07087847","phase":"NA","title":"Ex Vivo T-Cell-Depleted Haploidentical Transplantation Bridging With Chimeric Antigen Receptor T-cell Therapy and Prophylactic Memory T Cell Infusion for Acute Leukemia","status":"NOT_YET_RECRUITING","sponsor":"Ruijin Hospital","startDate":"2025-09-01","conditions":"Acute Leukemia, Acute Leukemia Refractory, Acute Myeloid Leukemia (AML)","enrollment":18},{"nctId":"NCT00710892","phase":"PHASE1","title":"CASPALLO: Allodepleted T Cells Transduced With Inducible Caspase 9 Suicide Gene","status":"ACTIVE_NOT_RECRUITING","sponsor":"Baylor College of Medicine","startDate":"2008-12","conditions":"Acute Lymphoblastic Leukemia, Non-Hodgkin's Lymphoma, Myelodysplastic Syndrome","enrollment":10},{"nctId":"NCT01945814","phase":"PHASE1","title":"Allogeneic Multivirus - Directed Cytotoxic T Lymphocytes (CTL)","status":"COMPLETED","sponsor":"Catherine Bollard","startDate":"2014-02","conditions":"EBV, CMV, Adenovirus","enrollment":27},{"nctId":"NCT03597594","phase":"PHASE1, PHASE2","title":"Haplocompatible Transplant Using TCRα/β Depletion Followed by CD45RA-Depleted Donor Lymphocyte Infusions for Severe Combined Immunodeficiency (SCID)","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2021-09-02","conditions":"Severe Combined Immunodeficiency","enrollment":4},{"nctId":"NCT06027879","phase":"PHASE1, PHASE2","title":"Anti-viral T-cell Therapy by Gamma Capture","status":"ENROLLING_BY_INVITATION","sponsor":"Paul Szabolcs","startDate":"2024-01-08","conditions":"Adenovirus, Cytomegalovirus Infections, Epstein-Barr Virus Infections","enrollment":25},{"nctId":"NCT03597321","phase":"PHASE2","title":"Early Prophylactic Donor Lymphocyte Infusion After Allo-HSCT for Patients With AML","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institut Paoli-Calmettes","startDate":"2020-09-07","conditions":"Acute Myeloid Leukemia","enrollment":124},{"nctId":"NCT07015684","phase":"PHASE1","title":"131I-apamistamab-based Conditioning for Hematopoietic Stem Cell Transplant (HSCT) in Advanced Sickle Cell Disease (SCD)","status":"RECRUITING","sponsor":"Columbia University","startDate":"2025-04-28","conditions":"Sickling Disorder Due to Hemoglobin S","enrollment":24},{"nctId":"NCT01350258","phase":"PHASE1, PHASE2","title":"Bone Marrow Transplant Using a Reduced Intensity Regimen That is Given in Two Steps","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2011-04","conditions":"Hematologic Malignancies, Acute Leukemia, Myelodysplastic Syndromes (MDS) Other Than RA or RARS Subtypes","enrollment":8},{"nctId":"NCT02203903","phase":"PHASE1","title":"Multi-institutional Prospective Research of Expanded Multi-antigen Specifically Oriented Lymphocytes for the Treatment of VEry High Risk Hematopoietic Malignancies","status":"RECRUITING","sponsor":"Catherine Bollard","startDate":"2015-01-01","conditions":"Relapsed/Refractory Hematopoietic Malignancies, Acute Myeloid Leukemia and MDS","enrollment":50},{"nctId":"NCT06997471","phase":"PHASE1","title":"Phase I Trial on the Safety of Delayed Infusion of a Naïve T Cell-Depleted Hematopoietic Graft With Memory T Cells in Solid Organ Transplant Recipients","status":"NOT_YET_RECRUITING","sponsor":"Francisco Hernández Oliveros","startDate":"2025-06","conditions":"Solid Organ Transplant Complications, Solid Organ Transplant Recipients, Solid Organ Transplant Rejection","enrollment":10},{"nctId":"NCT03537599","phase":"PHASE1, PHASE2","title":"Daratumumab and Donor Lymphocyte Infusion in Treating Participants With Relapsed Acute Myeloid Leukemia After Stem Cell Transplant","status":"TERMINATED","sponsor":"Sumithira Vasu","startDate":"2020-01-10","conditions":"Minimal Residual Disease, Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Recurrent Adult Acute Myeloid Leukemia","enrollment":4},{"nctId":"NCT01871441","phase":"PHASE2","title":"Haploidentical Donor Hematopoietic Stem Cell Transplant in Treating Patients With Hematologic Malignancies","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2013-05-17","conditions":"Malignant Neoplasm","enrollment":4},{"nctId":"NCT01350232","phase":"NA","title":"Treatment of Sickle Cell Anemia With Stem Cell Transplant","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2009-09","conditions":"Sickle Cell Anemia, Sickle Cell-hemoglobin C Disease, Sickle Cell-β0-thalassemia","enrollment":2},{"nctId":"NCT01350245","phase":"PHASE2","title":"Bone Marrow Transplantation of Patients in Remission Using Partially Matched Relative Donor","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2010-07","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndromes, Biphenotypic Leukemia","enrollment":28},{"nctId":"NCT05447663","phase":"PHASE1, PHASE2","title":"A Study of Siremadlin Alone and in Combination With Donor Lymphocyte Infusion in Acute Myeloid Leukemia Post-allogeneic Stem Cell Transplant","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2023-02-23","conditions":"Acute Myeloid Leukemia, Allogeneic Stem Cell Transplantation","enrollment":8},{"nctId":"NCT04857645","phase":"PHASE2","title":"ASTX727 and Donor Lymphocyte Infusions After Allogenic Stem Cell Transplantation in Very High Risk MDS or AML Patients","status":"COMPLETED","sponsor":"Groupe Francophone des Myelodysplasies","startDate":"2021-06-22","conditions":"MDS, AML","enrollment":57},{"nctId":"NCT04722029","phase":"PHASE1, PHASE2","title":"Pilot Study of Haploidentical Donor Adenovirus Specific T-lymphocytes to Treat Refractory Adenovirus Infections","status":"RECRUITING","sponsor":"Nationwide Children's Hospital","startDate":"2021-10-01","conditions":"Adenovirus Infection","enrollment":12},{"nctId":"NCT01459107","phase":"PHASE2","title":"Human Upper Extremity Allotransplantation","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2011-07-21","conditions":"Amputation, Traumatic, Wounds and Injuries, Hand Injuries","enrollment":30},{"nctId":"NCT01532635","phase":"PHASE2","title":"A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2012-03","conditions":"Hematologic Malignancy, Leukemia, Acute Lymphoblastic Leukemia","enrollment":4},{"nctId":"NCT00429143","phase":"PHASE1, PHASE2","title":"A Two-Step Approach to Bone Marrow Transplant Using Cells From A Partially-Matched Relative","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2006-01","conditions":"Hematologic Malignancies","enrollment":27},{"nctId":"NCT02548468","phase":"PHASE1","title":"Reduced Intensity Conditioning Before Partially Matched Donor Stem Cell Transplant in Treating Patients With Advanced Cutaneous T Cell Lymphoma","status":"WITHDRAWN","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2015-11-20","conditions":"Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent Mycosis Fungoides and Sezary Syndrome, Stage IIB Mycosis Fungoides and Sezary Syndrome","enrollment":""},{"nctId":"NCT01341301","phase":"PHASE2","title":"Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2010-05","conditions":"Hematologic Malignancy","enrollment":25},{"nctId":"NCT01982682","phase":"PHASE2","title":"Allogeneic Hematopoietic Stem Cell Transplantation for High-Risk Hematologic Malignancies Using One Haploidentical Donor","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2013-11-04","conditions":"Hematopoietic/Lymphoid Cancer","enrollment":41},{"nctId":"NCT04628338","phase":"EARLY_PHASE1","title":"IFN-γ to Treat Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) That Has Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation","status":"COMPLETED","sponsor":"Sawa Ito, MD","startDate":"2021-03-08","conditions":"Myelodysplastic Syndromes, Myeloid Leukemia, Allogeneic Stem Cell Transplantation","enrollment":8},{"nctId":"NCT04765449","phase":"PHASE1","title":"Transfer of Infection Fighting Immune Cells Generated in the Laboratory to High Risk Patients With COVID-19 Infection","status":"COMPLETED","sponsor":"Thomas Jefferson University","startDate":"2021-09-15","conditions":"Covid19","enrollment":30},{"nctId":"NCT05943067","phase":"PHASE1, PHASE2","title":"CD45RA Depleted DLI After TCRα/β Depleted Haploidentical HCT","status":"RECRUITING","sponsor":"University Hospital Tuebingen","startDate":"2023-04-27","conditions":"Hematologic Malignancy","enrollment":60},{"nctId":"NCT02566304","phase":"PHASE2","title":"Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2015-11-13","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia in Remission, Aplastic Anemia","enrollment":35},{"nctId":"NCT02100891","phase":"PHASE2","title":"Phase 2 STIR Trial: Haploidentical Transplant and Donor Natural Killer Cells for Solid Tumors","status":"TERMINATED","sponsor":"Monica Thakar","startDate":"2013-03-20","conditions":"Ewing Sarcoma, Neuroblastoma, Rhabdomyosarcoma","enrollment":15},{"nctId":"NCT01497184","phase":"PHASE1","title":"Infusion of Allogeneic CD19-Specific T Cells From Peripheral Blood","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2011-12","conditions":"Leukemia, Lymphoma","enrollment":95},{"nctId":"NCT06861348","phase":"PHASE2","title":"Effectiveness and Safety of InO±DLI for Relapsed B-ALL/LBL After Allo-HSCT","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2025-03-01","conditions":"Leukemia, Lymphocytic, Acute","enrollment":23},{"nctId":"NCT06835140","phase":"PHASE1","title":"CD123-CD16-NK Cells Immunotherapy for AML","status":"RECRUITING","sponsor":"Chunji Gao","startDate":"2025-02-21","conditions":"AML (Acute Myelogenous Leukemia), NK Cell, CD123+ Acute Myeloid Leukemia","enrollment":9},{"nctId":"NCT05066412","phase":"PHASE1","title":"Prophylactic CD45RA-depleted DLI After Haploidentical Transplantation/RIC","status":"RECRUITING","sponsor":"University Hospital, Geneva","startDate":"2024-11-26","conditions":"Hematologic Malignancy, Haplo-identical Stem Cell Transplantation","enrollment":12},{"nctId":"NCT03751709","phase":"PHASE1","title":"Blinatumomab Plus HLA-Mismatched Cellular Therapy for Relapsed/Refractory CD19+ ALL","status":"COMPLETED","sponsor":"Cedars-Sinai Medical Center","startDate":"2020-02-14","conditions":"B-Cell Acute Lymphoblastic Leukaemia, ALL, Adult, B-ALL","enrollment":22},{"nctId":"NCT06754540","phase":"PHASE2","title":"Azacitidine Combined with Donor Lymphocyte Infusion for Acute Myeloid Leukemia Post-transplant Relapse Prevention.","status":"NOT_YET_RECRUITING","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2025-01-16","conditions":"Acute Myeloid Leukemia (AML), Relapse","enrollment":51},{"nctId":"NCT06734520","phase":"NA","title":"Clinical Study of Super Transplantation in the Treatment of Severe β-thalassemia","status":"RECRUITING","sponsor":"Guangzhou Women and Children's Medical Center","startDate":"2024-10-01","conditions":"Thalassemia Majors (Beta-Thalassemia Major), Haplo-identical Donors","enrollment":3},{"nctId":"NCT05350163","phase":"PHASE1","title":"T-cell Receptor α/β Depleted Donor Lymphocyte Infusion","status":"TERMINATED","sponsor":"Guenther Koehne","startDate":"2022-04-05","conditions":"Lymphoid Leukemia, Acute, Myeloid Malignancy, Plasma Cell Tumor","enrollment":11},{"nctId":"NCT05042076","phase":"PHASE1","title":"BK With VST for Kidney Transplant Patients","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2021-12-16","conditions":"Kidney Transplant Infection, BK Virus Infection","enrollment":3},{"nctId":"NCT04582864","phase":"PHASE2","title":"Flotetuzumab for Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Following Allogeneic Hematopoietic Cell Transplantation (Allo-HCT)","status":"TERMINATED","sponsor":"Washington University School of Medicine","startDate":"2021-05-20","conditions":"Relapsed Acute Myeloid Leukemia","enrollment":11},{"nctId":"NCT03939585","phase":"PHASE1","title":"Preemptive Infusion of Donor Lymphocytes Depleted of TCR + T Cells + CD19+ B Cells Following ASCT","status":"WITHDRAWN","sponsor":"Leland Metheny","startDate":"2024-12-01","conditions":"Allogeneic Stem Cell Transplant Candidate, Acute Myeloid/Lymphoblastic Leukemia, Myelodysplastic Syndrome","enrollment":""},{"nctId":"NCT03524235","phase":"PHASE1","title":"Haploidentical Stem Cell Transplant with Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL","status":"COMPLETED","sponsor":"Noah Merin","startDate":"2018-07-18","conditions":"Multiple Myeloma, CLL, Chronic Lymphocytic Leukemia","enrollment":20},{"nctId":"NCT06011486","phase":"PHASE1","title":"Expansion of Virus-Specific Lymphocytes for Cell Therapy","status":"RECRUITING","sponsor":"Hospital Israelita Albert Einstein","startDate":"2024-06-10","conditions":"CMV Viremia, CMV","enrollment":10},{"nctId":"NCT06643221","phase":"EARLY_PHASE1","title":"Exercise as an Immune Adjuvant for Allogeneic Cell Therapies","status":"RECRUITING","sponsor":"University of Arizona","startDate":"2018-01-24","conditions":"Leukemia, Hematopoetic Stem Cell Transplantation, Donor Lymphocyte Infusion","enrollment":100},{"nctId":"NCT03766321","phase":"NA","title":"Fecal Microbiota Transplantation Effect on Amyotrophic Lateral Sclerosis Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Azienda Ospedaliero-Universitaria di Modena","startDate":"2020-07-01","conditions":"Amyotrophic Lateral Sclerosis","enrollment":42},{"nctId":"NCT06571825","phase":"PHASE4","title":"RIC Allo-HSCT vs. Venetoclax-Based Consolidation in Elderly AML Patients After First CR","status":"RECRUITING","sponsor":"He Huang","startDate":"2024-07-17","conditions":"Acute Myeloid Leukemia","enrollment":118},{"nctId":"NCT06316960","phase":"PHASE2","title":"Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT Mutation","status":"RECRUITING","sponsor":"Children's Hospital of Soochow University","startDate":"2024-03-01","conditions":"AML, Childhood, Relapse/Recurrence, Refractory AML","enrollment":50},{"nctId":"NCT03413800","phase":"PHASE2","title":"Len/Dex/DLI in Relapsed Multiple Myeloma After Allogeneic Stem Cell Transplant","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ciusss de L'Est de l'Île de Montréal","startDate":"2018-02-12","conditions":"Relapsed Hematologic Malignancy, Multiple Myeloma","enrollment":10},{"nctId":"NCT05009719","phase":"PHASE1, PHASE2","title":"Risk-adapted Donor Lymphocyte Infusion After Allo-HSCT in Children With Hematologic Malignancy","status":"COMPLETED","sponsor":"St. Petersburg State Pavlov Medical University","startDate":"2021-04-01","conditions":"Hematologic Malignancy","enrollment":50},{"nctId":"NCT06447090","phase":"PHASE2","title":"VMAC+DLI Treatment of Patients With Relapse of AML After Allo-HSCT","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2024-04-12","conditions":"Relapse Acute Myeloid Leukemia","enrollment":30},{"nctId":"NCT04364178","phase":"PHASE1, PHASE2","title":"Viral Specific T-Lymphocytes to Treat Adenovirus or CMV","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jessie L. Alexander","startDate":"2020-08-12","conditions":"Adenovirus, Cytomegalovirus Infections","enrollment":25},{"nctId":"NCT01597219","phase":"PHASE2","title":"Trial of Haploidentical Stem Cell Transplantation for Haematological Cancers","status":"COMPLETED","sponsor":"University College, London","startDate":"2013-03","conditions":"Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma, Acute Myeloid Leukaemia","enrollment":77}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1270,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["DLI","chemotherapy"],"phase":"phase_2","status":"active","brandName":"Donor Lymphocyte Infusion","genericName":"Donor Lymphocyte Infusion","companyName":"Antonio M Jimenez Jimenez","companyId":"antonio-m-jimenez-jimenez","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":4,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}